AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on ...

The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...

May 27 (Reuters) - AstraZeneca said on Wednesday the U.S. Food and Drug Administration has extended the decision deadline for ...

The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive ...

This extension follows an April vote by a majority of the FDA's advisory panel against the drug when used in combination with ...

Pharma company AstraZeneca has publicly released preclinical data from more than 50 of its medicines in order to find new drug combinations for cancer treatments. The data AstraZeneca released will be ...

AstraZeneca said the U.S. FDA has extended the decision date for its camizestrant new drug application, which seeks approval of the oral SERD in combination with CDK4/6 inhibitors as a first-line ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic ...

Achilles Therapeutics plc has announced the transfer of data and samples from its TRACERx Non-Small Cell Lung Cancer study and its Material Acquisition Platform (MAP) to AstraZeneca for a total ...

The CEO said positive Regal data could potentially help GPS gain broader NCCN recognition beyond the current AML setting. ・Earlier GPS data showed median survival of 35.5 months in older AML patients ...